OTCMKTS:MATN - Mateon Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0850 -0.03 (-26.72 %)
(As of 01/23/2019 04:00 PM ET)
Previous Close$0.1160
Today's Range$0.0770 - $0.09
52-Week Range$0.05 - $0.3096
Volume222,359 shs
Average Volume27,193 shs
Market Capitalization$3.52 million
P/E Ratio-0.16
Dividend YieldN/A
Beta2.19
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MATN
Previous SymbolNASDAQ:MATN
CUSIPN/A
Phone650-635-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.02) per share

Profitability

Net Income$-13,810,000.00

Miscellaneous

Employees5
Market Cap$3.52 million
OptionableNot Optionable

Mateon Therapeutics (OTCMKTS:MATN) Frequently Asked Questions

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics Inc (OTCMKTS:MATN) issued its quarterly earnings results on Wednesday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.02). View Mateon Therapeutics' Earnings History.

When is Mateon Therapeutics' next earnings date?

Mateon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 15th 2019. View Earnings Estimates for Mateon Therapeutics.

What price target have analysts set for MATN?

1 analysts have issued 12 month price targets for Mateon Therapeutics' shares. Their forecasts range from $1.00 to $1.00. On average, they expect Mateon Therapeutics' stock price to reach $1.00 in the next year. This suggests a possible upside of 1,076.5% from the stock's current price. View Analyst Price Targets for Mateon Therapeutics.

What is the consensus analysts' recommendation for Mateon Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mateon Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mateon Therapeutics.

Has Mateon Therapeutics been receiving favorable news coverage?

Press coverage about MATN stock has trended positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mateon Therapeutics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near term.

Who are some of Mateon Therapeutics' key competitors?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:
  • Dr. William D. Schwieterman, Chairman, CEO & Pres (Age 61)
  • Mr. Matthew M. Loar, Chief Financial Officer (Age 56)
  • Ms. Shari Annes, Exec. Officer of Investor Relations
  • Dr. Yuval Binur, Exec. VP of Financial
  • Ms. Pamela Ha, Controller

How do I buy shares of Mateon Therapeutics?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of MATN stock can currently be purchased for approximately $0.0850.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $3.52 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Mateon Therapeutics employs 5 workers across the globe.

What is Mateon Therapeutics' official website?

The official website for Mateon Therapeutics is http://www.mateon.com.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]


MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel